ERBB2 and cancer: After that, several randomized phase III trials in patients with HER2‐positive G/GEJ cancers also demonstrated the efficacy of HER2‐targeted therapies, including the TRIO‐013/LOGiC (lapatinib in combination with oxaliplatin and capecitabine as first‐line setting),5 the JACOB (trastuzumab plus pertuzumab and fluoropyrimidine and cisplatin as first‐line setting),6 the TyTAN (paclitaxel plus lapatinib as second‐line therapy)7 and the GATSBY (T‐DM1 as second‐line therapy) trials.8